SeptiCyte RAPID
Sepsis diagnosis in patients with suspected infection
ApprovedActive
Key Facts
Indication
Sepsis diagnosis in patients with suspected infection
Phase
Approved
Status
Active
Company
About Immunexpress
Immunexpress is a pioneer in host-response diagnostics for sepsis, a life-threatening condition that is the leading cause of death in hospitals. The company's core technology, SeptiCyte, quantifies specific gene expression markers from whole blood to rapidly identify sepsis, shifting the diagnostic paradigm from slow pathogen identification. Its commercial product, SeptiCyte RAPID, is a fully automated cartridge that runs on the Biocartis Idylla platform, providing results in one hour. The company aims to reduce sepsis mortality and the significant associated healthcare costs through early and accurate detection.
View full company profile